by Sam Eskandari | Oct 12, 2017 | News
October 11, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces the closing of a private placement of units. Under the terms of the Private Placement Offering, the Company will be issuing...
by Lui Franciosi | Oct 11, 2017 | News
October 11, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces the closing of a private placement of units. Under the terms of the Private Placement Offering, the Company will be issuing...
by Sam Eskandari | Aug 2, 2017 | News
August 2, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces that it has agreed to amend the terms of share purchase warrants (“Warrants”) originally issued in February 2017. Each...
by Sam Eskandari | Jul 24, 2017 | News
July 24th, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of Mr. Peter Doig to the advisory board of Veritas Pharma. Mr. Doig is a...
by Sam Eskandari | Jul 12, 2017 | News
July 11, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of RwE Growth Partners, Inc. to evaluate the Company’s $1.50 million investment...
by Lui Franciosi | Jul 10, 2017 | News
July 10, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd. (CTL) will be sending a team overseas next week...
